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1. Introduction
Vascular anomalies are heterogeneous group of congenital lesions of abnormal vascular devel‐
opment and may occur anywhere on the body. There is a primary distinction between a vascu‐
lar  tumor,  which  grows  by  cellular  hyperplasia,  and  a  vascular  malformation,  which
represents a localized defect in vascular morphogenesis. Due to the differences in biologic be‐
havior and radiographic features, malformations are further subdivided into low-flow and
high-flow lesions [1]. The common characteristic feature of all vascular anomalies is extreme
bleeding during surgical excision. Clinicians throughout the world use the classification by
Mulliken and Glowacki (1982) to classify these lesions. This classification is based on the vascu‐
lar lesion's histology, biological behavior and clinical findings [2]. Some of the lesions cause es‐
thetic problems, while some of them are malignant; thus, the therapeutic approach is variable.
Vascular tumors Vascular malformations
Slow-flow
Infantile hemangioma Capillary malformations
Congenital hemangioma Venous malformations
Tufted angioma Lymphatic malformations
Kaposiform hemangioendothelioma Fast-flow
Arteriovenous malformations
Table 1. Classification of vascular anomalies by Mulliken and Glowacki.
One of the most seen vascular tumors involving the head and neck region are hemangiomas.
These benign, generally painless lesions, are a proliferating mass of blood vessels that do not
© 2013 Fočo and Brkić; licensee InTech. This is an open access article distributed under the terms of the
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undergo malignant transformation; 60% percent of cases are localized in the head and neck
region. The rest are located in the trunk area (5%) and the extremities (15%)[3,4]. Hemangio‐
mas are mostly seen on the surface of the skin, although internal organs such as the liver,
larynx, lung or gastrointestinal tract may be also be affected. In the oral cavity, they may oc‐
cur on the tongue, lips, buccal mucosa, gingiva, palatal mucosa, salivary glands, alveolar
ridge and jaw bones [5,6]. In the majority of patients hemangiomas occure as a single lesion,
however 20% of patients may have more than one hemangioma [7].
In the literature, multiple hemangiomas are described as one of the components of so called
„PHACES“ syndrome. The syndrome includes: Posterior fossa defects, Hemangiomas, Arte‐
rial abnormalities, Coarctation of the aorta and cardiac malformations, Eye anomalies, and
Sternal defects [8].
In this chapter we will try to describe and document the clinical features and management
of the head and neck hemangiomas.
2. Hemangiomas
The term hemangioma was originally used to describe any vascular tumor-like structure,
whether it was present at or around birth or appeared later in life. The term is comprised of
the Greek words “haema” which means blood, “angeio” meaning vessel and “oma” meaning tu‐
mor. Histologically hemangiomas are composed of hyperplastic endothelial cells, which are
line the inner surface of the blood vessels in the human body, with the capacity for intensive
proliferation. The diameter of the blood vesels is important in classification of hemangiomas
to capillary and cavernous types [9]. The capillary type, also known as the strawberry he‐
mangioma is composed of small thin-walled vessels of capillary size that are lined by a sin‐
gle layer of flattened or plump endothelial cells and surrounded by a discontinuous layer of
pericytes and reticular fibers [9,10] (Figures 1and 2). It was first described in the literature in
1973 by Sznajder et al.[11], under the term "Hemorrhagic hemangioma" [10].
Figure 1. Capillary lip hemangioma
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Figure 2. Capillary lip hemangioma 20X
The cavernous type is characterized by large blood-filled spaces, so called cavities, that are
separated by a scanty connective tissue stroma [9]. Some lesions of hemangiomas are mixed,
which means that they have histologic components of both types [10] (Figures 3 and 4).
Figure 3. Cavernous lip hemangioma
Figure 4. Capillary hemangioma of lips 20X
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Clinically, hemangiomas are characterized as a soft, smooth or lobulated, sessile or pedun‐
culated mass and may be seen in any size from a few millimeters to several centimeters [12].
The color of the lesion ranges from pink to red or purple and blanches on the application of
pressure; hemorrhage may occur either spontaneously or after minor trauma [3]. Hemangio‐
mas are subdivided into two types: “infantile” and “congenital”[1,13]. However, there is a
hypothesis that these two entities are the variations of a single entity ab initio [14].
2.1. Infantile hemangiomas
Infantile hemangiomas are the most common tumors of infancy and occur in approximately
10% of infants by the age of 1 year, with a female predominance [15]. Studies suggest that
the ratio between female-male is 3-5 : 1, and a higher prevalence is seen in cases of prema‐
ture neonates especially when their weight at birth is less than 1500 g. [4,10]. As we men‐
tioned before, the most common localization of hemangiomas is the surface of the skin; thus,
hemangiomas usually appear as a barely visible pale, spot, red stain macula, telangiectatic
or pseudoecchymotic patch, 2-4 weeks after birth. Massive life threatening lesions usually
occur in the liver or central nervous system [16].
Infantile hemangiomas consist of rapidly dividing endothelial cells [13]. Chang et al. [10] state
that growth of infantile hemangiomas pass through 3 phases; Proliferation, involuting and in‐
voluted phases. The proliferative phase is characterized by rapid growth of the hemangioma
during the first year of life. A cellular mass without a defined vascular architecture and nascent
blood vessels with red blood cells are evident within the lumen [17]. This phase is the most pro‐
nounced during the first 3 - 6 months. However, it may be followed by a phase of slower
growth. Regardless of subtype or depth, hemangiomas reach an average of 80% of their final
size during the early proliferation stage, a stage that ends at a mean age of 3.2 months. Infantile
hemangiomas at the beginning of the proliferation phase, can show an early or late prolifera‐
tion growth pattern.This means that in cases with an early proliferation growth pattern prolif‐
eration starts earlier and essentially is complete after 5 months of age. While In cases of late
proliferation growth, proliferation starts later and lasts longer [10] (Figures 5A and 5B).
 
        (A)    (B) 
Figure 5. A) Infantile hemangioma of the cheek. (B) Frontal view
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The involuting phase follows the previous phase; thus in some cases it starts in a few
months, while in most cases by 12-18 months of age [10] and continues for 3 to 5 years [17].
Proliferation slows or stops in this phase, and histologic examination shows that the blood
vessel architecture becomes more obvious and vessel size enlarges [17]. It is important to
mention that in some cases different parts of the hemangioma may be under proliferation
and involuting at the same time [10]. Clinical signs of involution are characterized by a color
change from bright red to dull red to gray and usually begins centrally and spreads out over
the lesion with time. Generally, involution takes place at an estimated rate of 10% per year,
so that approximately 50% have involuted by 5 years of age, 70% by 7 years, and 90% by 9
years [10]. The involuted phase is the third phase in the hemangiomas and occurs at 5 to 8
years of age, at which point blood vessels are replaced with a fibrofatty residuum and capil‐
lary-sized channels [17]. In this phase depending on the size of the hemangiomas the form
changes and may include restoration to normal skin (in 50%) or fibro-fatty form of heman‐
gioma residuum and redundant skin. The later a hemangioma starts to involute, the higher
is their risk for residual changes after involution is completed. An involuted hemangioma
will never start to grow again; tumor growth in the completed involution phase is always
finished [10]. Glucose transporter-1 (GLUT-1) has been shown to be a specific marker for en‐
dothelium in all phases of infantile hemangioma, comparing with congenital hemangiomas,
in which this marker has not been detected [18,19].
2.2. Congenital hemangiomas
Congenital hemangiomas are fully developed at birth which do not exhibit accelerated post‐
natal growth. They may be diagnosed on a prenatal ultrasound. In 2000, congenital heman‐
giomas were identified as rapidly involuting congenital hemangiomas (RICH) and non-
involuting congenital hemangiomas (NICH) [10,13]. Both subtypes have many similarities,
such as appearance, location, size, and sex distribution [14,18]. Also they have some overlap‐
ping histologic features with infantile hemangioma [18].
2.2.1. Rapidly involuting congenital hemangiomas
Rapidly involuting congenital hemangiomas (RICH) are also present at birth as protuberant,
hemispherical, violaceous tumors with an average diameter of 5–6 centimeters, that often
have a central depression, scar or ulceration [18]. Histologic features are variable including
large and small lobules separated by dense fibrous tissue, and in some lesions there is a
sponge-like network of large capillaries [18]. RICH goes through a rapid regression phase
and may be completely gone by the time the child is 12 to 18 months old, leaving a mark as
some degree of atrothic or redundant skin [20]. In some cases rapidly involuting congenital
hemangiomas can undergo rapid but incomplete involution, with a resulting clinical ap‐
pearance and histology similar to noninvoluting congenital hemangiomas. Because of this, it
has been suggested that RICH and NICH may lie within the same spectrum of vascular tu‐
mors [14,18,20]. Rapidly involuting congenital hemangiomas are usually located on the
limb, head and neck regions and may be associated with decreased gioplatelets, thought to
be due to localized intravascular coagulation [21].
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2.2.2. Non-involuting congenital hemangiomas
Noninvoluting congenital hemangioma (NICH) is present at birth, grows proportionately
with the child, exhibits persistent fast-flow and does not regress [18]. This lesion occurrs
more often in male patients. Usually it is a single lesion with an average diameter of 5 cm.
Shapes may vary from round-to-ovoid or plaque-like, while the color may also be a variable
from pink to purple [18,22]. The overlying skin is frequently punctuated by coarse telangiec‐
tasia, often with central or peripheral pallor [22] (Figures 6A and 6B).
 
        (A)         (B) 
Figure 6. A) Congenital hemangioma. (B) Frontal view
Histologically, NICH is characterized by lobules with high cellular density: each lobule con‐
tains one or more large, irregular intralobular vessels surrounded by multiple small vessels
with indistinct lumens [18].
Congenital hemangioma Infantile hemangioma
Present at birth. Visible between 2 weeks and 4 months of age.
Growth is complete at birth or may grow proportionately
as the child grows.
Grows rapidly for about 6 to 12 months (average is around
8 months).
Males : females = 1:1 Males : females=1: 3-5
Less common but not rare. Common [4-5 percent incidence in newborns).
Rapid or no involution (shrinking). Slow shrinking that takes months or years.
GLUT-1 negative GLUT-1 positive
Proliferating phase characterized by large and irregularly
shaped vessels
Proliferating phase characterized by small regular
capillaries
Table 2. Differences between congenital hemangioma and infantile hemangioma
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3. Etiology
Hemangioma development is also known as hemangiomagenesis [23]. Although pathogene‐
sis and origin of hemangioma remains incompletely understood, medical literature de‐
scribes different hypothesis for its development in which extrinsic and intrinsic factors play
an important role of endothelial cell proliferation. Placental, estrogen signaling, genetic
theory, theory of hypoxia and role of the growth factors involved in angiogenesis such as
vascular endothelial growth factor (VEGF), tissue growth factor beta (TGF-beta) and insulin-
like growth factor-2 (IGF-2), are just some of theories of hemangioma development.
3.1. Placental origin theory
In the placental theory, there is an opinion that the infantile hemangioma originated from
placental trophoblast [23-25]. The hypothesis is based on shared expression of distinct endo‐
thelial markers such as GLUT1, Fcγ RII, α2-laminin, Lewis Y antigen, type III iodothyronine
deiodinase, indoleamine 2,3-deoxygenase, and insulin-like growth factor 2 in the placenta
and hemangioma [22]. Also an incidence of hemangiomas occurrence is more common in in‐
fants born to mothers with placental abnormalities, such as preeclampsia and placenta pre‐
via, as well as those exposed to chorionic villous sampling (CVS)[26,27], which once more
contribute to the placental theory of hemangioma development.
3.2. Estrogen signaling theory
Estrogen signaling theory suggests that because of increased incidence in females, evidence
of estrogen receptor (ER) positivity in endothelian cells of proliferating hemangiomas, and
elevated levels of circulating 17-β estradiol (which is known to be protective for hypoxia-
induced apoptosis) in affected children, the estrogen may be involved in the growth of in‐
fantile hemangioma [16,28]. In the perinatal period free estrogen increases, which may
stimulate areas of hypoxic endothelium to induce hemangioma formation [16,29].
3.3. Hypoxia theory
In the hypoxia theory, the hypoxic environment leads to an upregulation of factors that pro‐
mote the recruitment and proliferation of endothelial progenitor cells. These factors include;
hypoxia inducible factor-1alpha (HIF-1alpha), stromal cell derived factor-1alpha (SDF-1al‐
pha) and vascular endothelial growth factor (VEGF) [18,27].However,in this theory there is
link between hypoxia and estrogen contribution in hemangioma formation. In explanation,
increased estrogen hormone levels in the postpartum period create a milieu that promotes
new blood vessel development and growth of the lesion [27,29].
3.4. Theory of angiogenesis involved growth factors
Growth factors specifically involved in angiogenesis such as vascular endothelial growth
factor(VEGF), insulin-like growth factor-2 (IGF-2) and tissue growth factor beta (TGF-be‐
ta)  are  often  increased  during  the  proliferation  phases  of  hemangioma  growth;  while
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during  the  involution  phase  of  hemangioma,  they  decrease  [30].Vascular  endothelial
growth factor (VEGF) was originally identified as an endothelial cell specific growth fac‐
tor  stimulating  angiogenesis  and  vascular  permeability  [18,29].  Studies  suggest  that  in
the patients with proliferating hemangiomas, the serum vascular endothelial growth fac‐
tor concentrations are significantly higher than in patients with involuting hemangiomas,
vascular  malformations  and  healthy  patients  [18,31,32].  Insulin-like  growth  factor-2
(IGF-2)  is  known  to  be  highly  expressed  in  infantile  and  congenital  hemangiomas[19].
Links between this  factor and angiogenesis  would be that  IGF-2 induce hypoxia-induci‐
ble  factor  1-α  (HIF-1α),  and  HIF-1α  is  known  to  up-regulate  glucose  transporter-1
(GLUT-1) [18]. However, GLUT-1 is specific only for infantile hemangiomas [19]. An ex‐
pression  of  tissue  growth  factor  beta  (TGF-beta)  in  proliferative  hemangioma is  signifi‐
cantly higher comparing with the other stages of hemangiomas [33,34].
3.5. Genetic theory
In the genetic theory, a hereditary component is presumed to be the cause of hemangiomas
[34,35]. Hemangioma may be passed from parent to child as an autosomal dominant trait
with incomplete penetrance [35]. Although the gene responsible for hemangioma/malforma‐
tion development is not identified, there is an opinion that the gene locus could be on chro‐
mosome 5q [34]. Genetics and race may play an important role in hemangiomas occurrence,
due to the fact that the majority of hemangiomas occur in infants of Caucasian descent, rare‐
ly in Asian and almost never occur in infants of African-American descent [4,36].
4. Clinical findings
The majority of hemangiomas are located on the skin as a soft, smooth or lobulated, sessile
or pedunculated masse. Their size may vary from several millimeters to several centimeters
[1,3]. The color of the lesions range from pink to red purple and tumors blanch on the appli‐
cation of pressure [3]. Hemangiomas can be superficial, deep, or compound [1]. The superfi‐
cial hemangioma (affecting only the superficial skin) is red and nodular with no
subcutaneous component. A deep hemangioma (affecting only the deep skin) presents as a
protrusion with an overlying bluish tint or telangectasia. Compound (mixed) hemangioma
has both deep and superficial components [1,10]. By statistics, 60% of hemangiomas are su‐
perficial, 15% are deep, and 25% are compound [10].
More than 80% of hemangiomas are solitary lesions [7]. Hemangiomas may be further sub‐
divided into focal, multifocal and segmental hemangiomas. Focal hemangiomas are local‐
ized, unilocular lesions which adhere to the phases of growth and involution. Multifocal
hemangiomas usually involve a visceral organs, while segmental hemangiomas are more
diffuse plaque-like and can lead to untoward functional and esthetic outcomes [1]. Deep
segmental hemangiomas proliferate longer, while superficial and focal hemangiomas start
to involute earlier [10].
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In 60% percent of cases hemangiomas are localized in the head and neck region with the dis‐
tribution of the trigeminal nerve [1,3,4]. They can be localized even in the infraorbital nerve
canal [37].A beard-like distribution is associated with a subglottic hemangioma [1]. In cases
of deeply located hemangiomas such as those in eye, symptoms might be amblyopia (lazy
eyes) and distortion of the cornea. Hemangiomas in the respiratory system can block breath‐
ing, while those located in the liver may be asymptomatic, unless due to huge size stresses
the heart. In the oral region, hemangiomas are not that common. If they are present, they
may occur on tongue (Figure 7), lips, buccal mucosa, gingiva, palatal mucosa, salivary
glands, alveolar ridge and jaw bones [3,5,6].
Figure 7. Hemangioma of the tongue.
In cases of gingival hemangiomas, the lesions often appear to arise from the interdental gin‐
gival papilla and spread laterally to involve adjacent teeth [3]. Masticatory trauma plays an
important role in development of symptoms such as bleeding of the gingiva or tongue. In
hemangiomas of the jaw, clinical signs usually develop after extraction of tooth associated
with the lesion. Oral bleeding may be spontaneous in cases that violate the epithelial base‐
ment membrane by penetration of the hemangioma [38].
4.1. Diagnosis
The diagnosis of a hemangioma is based on clinical history, physical, radiographic, laborato‐
ry and pathohistological examinations. In previous parts of the chapter we have described
clinical and histological findings of hemangiomas.
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Radiographic examinations are usually performed in cases of deeply positioned hemangio‐
mas. The examinations include conventional radiography with panoramic radiographs, an‐
giography, computed tomography (CT), magnetic resonance imaging (MRI) and Doppler
ultrasonography. Conventional radiography is used mostly for diagnosis of bone hemangio‐
mas. Findings are multicystic “soap bubble” appearances. On CT the changes are in bone
trabeculae. In diagnosis of soft tissue hemangiomas CT, MRI and Doppler ultrasonography
are performed. MR imaging can be used to classify vascular malformations as either low-
flow or high-flow lesions, especially when combined with dynamic contrast-enhanced MR
angiography. Also, evaluation of extraosseous extension can be diagnosed by MRI [39].
Doppler ultrasonography is the least invasive and most cost-effective imaging to document
blood flow in hemangiomas.
Pathohistological examinations for diagnosis and distinguishing hemangiomas from other
lesions sometimes do not offer a proper diagnosis.  For example in the differential  diag‐
nosis from oral pyogenic granuloma, both lesions share the histologic designation "capil‐
lary hemangioma“ [38].
Laboratory examinations are important in differential diagnosis of hemangiomas to the oth‐
er arteriovenous malformations and pathologies. Glucose transporter-1 (GLUT-1), vascular
endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2) and tissue growth
factor beta (TGF-beta) are just some of the examinated factors. For example, as we men‐
tioned before, positive staining for GLUT-1 is considered highly specific and diagnostic for
hemangioma, and it is useful for making differential diagnosis between hemangioma and
other vascular lesions clinically related to it [12].
4.2. Differential diagnosis
Differential diagnosis of the head and neck hemangiomas include several lesions such as
pyogenic granuloma, chronic inflammatory gingival hyperplasia, epulis granulomatosa, te‐
langiectasia, angiosarcoma, squamous cell carcinoma, and other vascular appearing lesions
such as Sturge Weber syndrome.
Rapidly involuting congenital hemangioma (RICH) as single large tumor associated with le‐
sional ulceration and congestive heart failure, can easily be confused with congenital infan‐
tile fibrosarcoma and arteriovenous malformation [19]. Because of this, arteriography in
order to exclude infantile fibrosarcoma and arteriovenous malformation play an important
role in proper diagnosis. In these cases biopsy is not advantageous because of the high risk
of bleeding. It may be reasonable only in cases of previously reported congenital infantile
fibrosarcoma [19].
Noninvoluting congenital hemangioma (NICH) may vary from plaque-like with a pink or
purple color, to prominent overlying coarse telangiectasias, and be difficult to diagnosed or
distinguish from the other, even malignant pathologic lesions [20].
The differentiation between hemangioma and vascular malformations is made on the basis
of clinical appearance, histopathology, and biological behaviour [12].
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5. Complications
Complications associated with hemangiomas may include;bleeding, ulceration, infection,
airway obstruction or visual complications. The incidence of complications such as ulcera‐
tion is between 5-13% [3]. Ulceration usually occurs in the proliferative phase because the
growth of the lesion surpasses epidermal elasticity and blood supply. Large lesions and le‐
sions in the area of the skin flexion such as intertriginous, perineal, and perioral are more
prone to develop ulcerations [8,26]. Bleeding and infection development are in many cases
just sequels of ulceration [8]. In the oral region bleeding and infection may develop after
masticatory minor trauma. Airway obstruction is caused by hemangiomas located in the res‐
piratory system. Infantile hemangioma lesions in a “beard-like” distribution along the jaw
are at increased risk of airway involvement. These infants, therefore, need to be monitored
frequently for signs of respiratory distress, including a barking cough and/or progressive
stridor, especially during the first several months of life [8]. Amblyopia "lazy eyes“ and dis‐
tortion of the cornea are complications associated with periocular-located hemangiomas
[8,26]. Strabismus, myopia, tear duct obstruction, proptosis, and ptosis are other complica‐
tions associated with the ocular hemangiomas [8].
6. Management
Management of hemangiomas include sevaral factors including age of the patient, type, size,
dissemination and depth of penetration [3,12]. There is an opinion that only 10–20% of heman‐
giomas due to the size, location, stages of growth or regeneration, functional compromise and
behaviour, require treatment [12]. For example a large lesions prone to ulceration, bleeding, in‐
fection, vital and functional compromises must be treated. Treatment options include: surgery,
laser surgery, local and systemic use of corticosteroids, Interferon alfa, Imiquimod, Proprano‐
lol, Pingyangmycin. Each treatment modality has its own risks and benefits [12].
6.1. Surgery
Surgical approach to hemangiomas is still the most performed procedure, isolated or in combi‐
nation with another treatment modalities. Although in more than 80% of hemangiomas the ob‐
servation is suggested, due to spontaneous involution of the lesions, in some cases such as lip
hemangiomas the '' wait and see“ approach [40] is not welcome. Lip hemangiomas are highly vis‐
ibile, prone to ulcerations and have a tendency to a leave residual deformity even after resolution
[40,41]. Ulcerations are mostly seen during the proliferative period and can lead to increased
scarring, loss of lip contour, and disfigurement [41]. The mentioned authors [40,41] stated bene‐
fits of early surgical excision of lip hemangiomas. Even lip hemangiomas that cross the vermilio-
cutaneous junction can be excised and lip contour achieved without the need to extend scars
beyond the junction [41]. It is worth mention that in a study by Chang et al. [41], a higher inci‐
dence of lower lip hemangiomas, comparing with hemangiomas located in the upper lip was re‐
ported.  In  cases  of  localized  cutaneous  infantile  hemangiomas,  surgical  excision  is  also
Vascular Anomalies of the Maxillofacial Region: Diagnosis and Management
http://dx.doi.org/10.5772/53853
313
suggested to be performed to minimize the scar after the involuted hemangioma [42,43]. As we
know, in proliferative phase, the hemangioma acts like a tissue expander, destroying elastic fi‐
bers or causing ulceration resulting in telangiectases, cutaneous laxity, scarring, and fibrofatty
residuum [42]. Two types of surgical excisions named lenticular and circular, may be performed
in therapy of hemangiomas [42-44]. Lenticular excision of hemangiomas results in increased scar
length as compared with the original lesion [43], while circular excision and purse-string closure
reduces both the longitudinal and transverse dimensions and converts a large circular lesion into
a small ellipsoid scar [42-44]. Also another advantage of the circular excision is minimal distor‐
tion of surrounding structures [42]. Vlahović et al. concluded that the circular excision and purse-
string suture technique are applicable for hemangioma at any stage [44]. In 1985, Popescu [45],
presented a new approach to cavernous haemangioma in different sites, which included an in‐
tratumoral ligation. The technique completely interrupted the intratumoral blood flow, result‐
ing in obstruction of vascular lumina, endothelial atrophy, blood clot organization in the small
diverticula between them and also subsequent fibrous hyperplasia. In this way the hemangioma
mass was split into segments, thus the blood flow was eliminated (Figures 8A and 8B).
 
       (A)    (B) 
Figure 8. A) Preoperative view of the patient with diagnosed congenital hemangioma.(B) Postoperative view.
High vascularization of hemangiomas is one of reasons why these lesions are prone to
bleeding spontaneously or during the trauma. In the case of head and neck hemangiomas,
ligations of the external carotid, facial artery and afferent vessels of the tumour with the aim
of decreasing blood supply to the vascular dilatations and channels are performed. Howev‐
er, the results are not so good. In the 1990's a new method of coagulation in cavernous he‐
mangiomas was presented [46]. The use of percutaneous copper needles to induce
therapeutic coagulation in cavernous hemangiomas, followed by surgery was effective in
cases of facial, cervical and oral hemangiomas [47]. The method [46] was presented as a sim‐
ple, safe and effective treatment for cavernous hemangiomas.
6.2. Laser surgery
From the last few decades, laser surgery has emerged as one of the most performed thera‐
peutic approaches for vascular lesions and hemangiomas. During the 1980's, lasers such as
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argon and carbon dioxide were mostly used for the excision of capillary / cavernous heman‐
giomas because of the low incidence of bleeding [48]. From 1990's the neodymium: ytrium-
aluminum-garnet (Nd:YAG) laser started to be in used as a new and effective mode of
treatment for vascular lesions [49,50]. Intralesional photocoagulation is the base of the
Nd:YAG laser efficacy. Many studies [49-53] evaluated hemangioma outcomes after laser
treatment. After a follow up of at least 6 months, reduction in lesion size was noted, espe‐
cially in cases of large lesions. The authors concluded that the Nd:YAG laser is a safe and
effective tool for the treatment of large lesions [49,50]. However, complications such as su‐
perficial ulceration or scarring, may be expected [51]. In some cases due to the fact that he‐
mangioma formations do not involute completely, surgical resection or treatment of local
steroid injections due to lesion fibrosis may be performed [53].
6.3. Cryotherapy
Superficial cryotherapy with carbon dioxide snow may be effective in the case of facial he‐
mangioma, but this method is completely ineffective in the management of tuberous or cav‐
ernous haemangiomas [46].
6.4. Corticosteroids
In conservative therapy of hemangiomas, the corticosteroids are the first choice. They can be
used systemic or locally. Growth disturbance and risk of malformation in children is associ‐
ated with the use of corticosteroids [46].
6.4.1. Systemic corticosteroids
Prednisone as the representative of systemic corticosteroids has found its place in heman‐
gioma treatment. Although the mechanism of action is unknown, there are suggestions that
corticosteroids inhibit the expression of VEGF-A by hemangioma-derived stem cells and si‐
lencing of VEGF-A expression in these cells inhibited vasculogenesis in vivo [54]. Also they
may be responsible for vasoconstriction of arterioles and precapillaries [55]. Daily doses are
usually 2-4 mg/kg [56,57] and it is mostly in use for treatment of cutaneous infantile heman‐
giomas. Parotid hemangiomas for example may be resistant to this therapy [56]. Reasons for
this may be differences in drug metabolism, caliber of blood vessels, and/or blood flow in
the parotid gland [56].Benett et al. [57] in their study revealed that the dose of the drug plays
an important role in the lesional response, thus higher doses show significantly higher re‐
sponses and results are more visible, if initiated during the initial proliferative phase. Sys‐
temic corticosteroids are mostly in use for treatment of large and aggressive lesions.
The long duration of therapy made it difficult to determine the effect the corticosteroid ther‐
apy had on the hemangiomas vs spontaneous involution [57]. Systemic corticosteroids carry
well-documented risks, such as disseminated varicella and herpes infections, and some au‐
thors have questioned their efficacy [47].




Local corticosteroids in the form of intralesional corticosteroid injections are in use for treat‐
ment of small, bossed, facial hemangiomas. The response to the therapy is equal to response
to systemic therapy. The dose of local corticosteroids is 20mg/ml in the form of triamcino‐
lone acetonide [58,59]. In 6-8 week intervals, 3-5 injections are needed and during applica‐
tion, surrounding areas must be compressed [59]. Contraindications for local corticosteroids
are necrosis and secondary infection of the lesion. Local corticosteroids may be responsible
for embolization of small arteries, such as retinal artery, thus their use in cases of eye he‐
mangiomas must be limited [59].
6.5. Interferons ALFA-2a, ALFA 2-b
Interferon alfa inhibits the development of new blood vessels from preexisting vessels. Usu‐
ally therapy with interferon is used when hemangiomas do not respond to the coricosteroid
therapy. Daily doses of interferon are 3 million U/m2 in the form of subcutaneous injections
[56,58]. Interferon is not a very safe drug. It was shown that it is neurotoxic, thus neurologic
follow up is necessary [58]. Also as in the case of systemic corticosteroids, parotic hemangio‐
mas do not respond to their effects [56]. Complications associated with interferon therapy
include neutropenia, abnormalities in liver enzymes and spastic diplegia [58].
6.6. Sclerotherapy
Sclerotherapy is a procedure in combination with surgery, by which application of some
chemicals such as hypertonic saline, sodium tetradecyl sulfate, 5% ethanolamine oleate, 5%
sodium morrhuate, sodium psylliate, pyngyangmycin, quinine urethrone, 5% and 1% poli‐
docanol solutions produce thrombosis of the vessels and an indurated mass [60-62]. The
procedure is most effective when the vascular spaces are small or when blood flow is slow
[62]. Hemangioma size after sclerotherapy is decreased and its nature changes to a more fi‐
brous consistency, thus surgical resection of the lesion is easily performed with minimal
bleeding [61,62]. Complications of sclerotherapy may include ulceration, inflammatory reac‐
tion, necrosis and scar, mostly when the sclerosing agent is applied directly to connective
tissue or when a vascular leak caused by excessive injection pressure is identified [61].
6.7. Propranolol
In  2008.  Leaute-Labreze  et  al.[63]  presented efficacy  of  sympatholytic  non-selective  beta
blocker  known as  propranolol,  in  therapy of  infantile  hemangiomas.  The mechanism of
action is unknown, but there are reports that suggest that within 24-48 hours, hemangio‐
mas  respond to  therapy by size  reduction and changes  in  color  [64].  Although authors
report  that  the  drug  is  most  effective  in  cases  of  proliferative  hemangiomas,  results  of
some cases  have  shown that  hemangiomas  in  the  post-proliferative  stage  respond well
[64,65]. A daily dose of propranolol is 2mg/kg and it is given in three equally doses [65].
Taking in consider that propranolol is a relatively new drug for treatment of infantile he‐
mangiomas,  there is  little  known of  its  side effects.  For  example,  while  Zvulunov et  al.
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[66]  report  no significant  side effects,  some other  authors  suggest  that  propranolol  may
mask the clinical signs of early cardiac failure and diminish cardiac performance. Also it
may blunt the clinical features of hypoglycemia[67].
6.8. Imiquimod
Imiquimod is a drug with ability to induce the production of interferon, tumor necrosis
factor-alpha  and the  antiangiogenesis  factor  tissue  inhibitor  of  matrix  metalloproteinase
[68].  In  topical  form as  Imiquimod 5% cream may be effective in therapy of  superficial
infantile  hemangiomas  [69-71].  Some  authors  suggest  that  the  Imiquimod  should  be
avoided in those hemangiomas located around the cavities and skin folds [69]. The most
common side effects of topical Imiquimod are slight skin erythema and crusting [69,70].
Post-treatment skin reactions are texture changes,  which in cases without crusting invo‐
luted to almost normal skin [70].
6.9. Bleomycin
Bleomycin is an antibiotic from the culture medium of streptomyces verticullust, with prop‐
erties of an anticancer agent [72]. In treatment of infantile hemangiomas, bleomycin in the
form of bleomycin A5 may be used isolated [73] or in combination with prednisone [72,73].
As intralesional injection its efficacy is based on a high sclerosing effect on vascular endothe‐
lium [74], thus it is most effective in cases of proliferating infantile hemangiomas, inhibiting
the proliferation [72]. The results of studies have show a high incidence of complete heman‐
gioma involutions, better recovery of skin color and less scar forming in small hemangio‐
mas, after bleomycin therapy [72-74]. Side effects of therapy include edema, ulceration,
gastrointestinal symptoms such as nausea and lack of appetite [72,74], cellulitis and transi‐
ent hair loss [73].
7. Conclusion
Each treatment modality of head and neck located hemangiomas has its own risks and bene‐
fits. In cases of infantile hamangiomas, oral propranolol is very useful and well tolerated,
having minimal side-effects in the resolution of the hemangiomas. In adult patients surgical
treatment including intratumoral ligation, isolated or in combination with laser or sclero‐
therapy is the most performed therapeutic option.
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